Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 62Leukemia, Myeloid, Acute 51Myelodysplastic Syndromes 39Leukemia 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Leukemia, Myelomonocytic, Chronic 34Leukemia, Lymphocytic, Chronic, B-Cell 26Blast Crisis 23Myeloproliferative Disorders 20Congenital Abnormalities 20Multiple Myeloma 17Anemia, Refractory 15Myelodysplastic-Myeloproliferative Diseases 14Hodgkin Disease 14Anemia 14Primary Myelofibrosis 13Lymphoma 13Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 13Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Chronic-Phase 12Thrombocytopenia 11Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 11Leukemia, Myeloid, Accelerated Phase 11Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Large B-Cell, Diffuse 10Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Follicular 9Leukemia, Prolymphocytic 8

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Clonal Cytopenia of Undetermined Significance × Classical hematology × Clear all
NCT05102370 2026-01-27

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
4 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡